Fox Chase’s Cihangir Duy Receives an American Society of Hematology 2023 Scholar Award
February 17th 2023Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology 2023 Junior Faculty Scholar Award in basic/translational research.
Fox Chase Graduate Student Billy Truong Recognized With ASH Abstract Achievement Award
December 19th 2022Billy Truong, a doctoral candidate at Fox Chase Cancer Center, was awarded the American Society of Hematology Abstract Achievement Award for a poster that he presented at the 64th ASH Annual Meeting and Exposition.
Fox Chase Study Reveals Mechanism for Repairing DNA Damage Caused by Environmental Triggers
December 2nd 2022It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.
Immune Checkpoint Inhibitors at ASCO: Long-term Efficacy Data Mount
July 25th 2022Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.
Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer
Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.
Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC
The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.